20120172.TNBC
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.560
- E2F_TARGETS+0.540
- MYC_TARGETS_V2+0.440
- MITOTIC_SPINDLE+0.350
- WNT_BETA_CATENIN_SIGNALING+0.350
- MYC_TARGETS_V1+0.270
- NOTCH_SIGNALING+0.200
- HEDGEHOG_SIGNALING+0.100
- TNFA_SIGNALING_VIA_NFKB+0.090
- KRAS_SIGNALING_DN+0.080
Top 10 suppressed
- PROTEIN_SECRETION-0.440
- INTERFERON_ALPHA_RESPONSE-0.430
- ADIPOGENESIS-0.370
- ANDROGEN_RESPONSE-0.350
- FATTY_ACID_METABOLISM-0.320
- INTERFERON_GAMMA_RESPONSE-0.300
- APOPTOSIS-0.290
- BILE_ACID_METABOLISM-0.290
- ANGIOGENESIS-0.270
- OXIDATIVE_PHOSPHORYLATION-0.270
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-E9-A1N8-01A-11R-A144-07 | — | E | 0.868 |
| 2 | SRR8613730 | — | D | 0.856 |
| 3 | TCGA-B6-A0IQ-01A-11R-A034-07 | — | E | 0.843 |
| 4 | SRR10842373 | — | — | 0.827 |
| 5 | SRR29022831 | — | E | 0.816 |
| 6 | MNG465 | — | — | 0.812 |
| 7 | SRR8518126 | — | E | 0.811 |
| 8 | TCGA-A1-A0SK-01A-12R-A084-07 | — | E | 0.810 |
| 9 | SRR8752373 | — | — | 0.810 |
| 10 | BS_QB84TBA3 | high-grade glioma | — | 0.802 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.560 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.540 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.440 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.350 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.350 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.270 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.200 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.100 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.090 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.080 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.050 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.050 | Idelalisib | — uncovered |
| HYPOXIA | 0.040 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.040 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.010 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.010 | Inavolisib | — uncovered |